Friday, September 10, 2010

Site Search

FDA/CMS Summit

Last Updated on Tuesday, 30 October 2007 02:53 Written by admin Tuesday, 30 October 2007 02:53

If you make FDA/CMS Summit an annual must-attend like hundreds of other pharmaceutical and biotech leaders, keep ahead of the curve and mark your calendars NOW.

Key Benefits for Attending FDA/CMS Summit:

  • Hear the critical trends and changes that affect your regulatory strategy successful strategies for dealing with FDA and CMS
  • Walk away with practical, real life lessons from some of the most experienced pharmaceutical and biotechnology executives on how they handle regulatory obstacles
  • Get face-to-face access to the top regulatory thought leaders and policy makers
  • Benchmark your regulatory strategy against all the major pharmaceutical and biotech companies

Hear the Regulators’ First-Hand Perspectives on:

  • User feesdotcom/conferences/inde
  • Health care fraud prosecutions, especially in the new prescription drug benefit
  • Drug development and NDA approval strategies
  • Drug safety, risk management and post-market surveillance
  • Biogenerics/follow-on biologics
  • Personalized medicine
  • Pharma marketing and promotions regulation and enforcement
  • Marketing and promotion regulation and enforcement
  • Medicaid and Medicare reimbursement
  • Medicare Part D
  • Critical Path Initiative
  • Pricing Strategies

Last year’s FDA/CMS Summit highlighted all of the biggest names in government: Andrew von Eschenbach, Acting Commissioner, FDA, Mark McClellan, MD, CMS Administrator, Steven Galson, MD, Director, Center for Drug Evaluation and Research, FDA, and Scott Gottlieb, MD, Deputy Commissioner for Medical and Scientific Affairs, FDA.

A small sample of companies sending their teams to FDA/CMS Summit include: AstraZeneca

Bayer HealthCare Pharmaceuticals, Inc.

Boehringer Ingelheim Corp.

Bristol-Myers Squibb Company

Cephalon Inc.

Eli Lilly & Company

Genentech Inc.

GlaxoSmithKline

Hoffmann-La Roche Inc.

Johnson & Johnson

MedImmune, Inc.

Novartis

Novo Nordisk, Inc.

Pfizer

Purdue Pharma L.P.

Roche

Sanofi Aventis

Schering-Plough Corporation

Takeda Pharmaceuticals

TAP Pharmaceutical Products Inc.

UCB Pharma

Wyeth

This entry was posted on Tuesday, October 30th, 2007 at 2:53 pm and is filed under Press Releases, USA and Canada. You can follow any responses to this entry through the RSS 2.0 feed. Responses are currently closed, but you can trackback from your own site.